Hormone therapy and ovarian cancer: incidence and survival.

OBJECTIVE: We conducted a population-based case-control study to investigate the association between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer cases to determine the association of HT use with ovarian cancer mortality. METHODS: Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-79 years were diagnosed in Massachusetts and Wisconsin between 1993-1995 and 1998-2001 and matched to similarly aged controls (n = 5,808). Study subjects were interviewed by telephone, which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or estrogen plus progestin (EP). Ovarian cancer cases were followed-up for mortality through December 2005. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer mortality. RESULTS: Ever use of HT was significantly associated with an increased risk of ovarian cancer (odds ratio 1.57, 95% CI 1.31-1.87). The excess risk was confined to women who used E-alone preparations (OR 2.33, 95% CI 1.85-2.95). No significant associations were detected between pre-diagnosis HT use and ovarian cancer survival. CONCLUSIONS: Hormone therapy increases risk of ovarian cancer among E-alone users, but there is no substantial impact on survival after diagnosis

Maternal Pre‐Pregnancy Body Mass Index Is Not Associated With Infant and Young Child Feeding in Low‐Income Mexican Children 1–24 Months Old

Pre-pregnancy overweight and obesity is associated with shorter breastfeeding (BF) duration. Whether pre-pregnancy overweight and obesity is associated with other aspects of infant and young child feeding (IYCF) hasnot been investigated. We used data from 370 children born January 1999–September 2001 in a semi-urbancommunity in Morelos, Mexico, where information on how they were fed was available at 1, 3, 6, 9, 12, 18 and 24months of age. We modified the World Health Organization’s dietary diversity indicator to assess the quality ofthe complementary foods. An index that included BF, quality of complementary foods and other behaviours wasconstructed to measure IYCF. We used survival analysis to examine the association of pre-pregnancy body massindex (pBMI) category and BF duration and mixed models for quality of complementary food and IYCF index.Mean maternal pBMI was 24.44.1; 31% were overweight, and 9% were obese. pBMI was not associated with BF duration. Quality of complementary food improved over time (6 months, 1.3 1.3; 24 months, 3.8 1.04).Compared with normal-weight women, overweight and obese women were more likely to feed from more foodgroups (0.24 0.11 point,P=0.03), but this did not improve diet diversity from 6 to 24 months. IYCF indexdecreased throughout follow-up (1 month, 7.8 2.4; 24 months, 5.5 1.8), and pBMI was not associated withIYCF (-0.11 0.13 point,P=0.4). We conclude that heavier women were not engaging in IYCF behaviours thatwere distinct from those of normal-weight women from 1 to 24 months post-partum

Pre-Diagnosis Oophorectomy, Estrogen Therapy and Mortality in a Cohort of Women Diagnosed with Breast Cancer

Introduction: Pre-diagnosis oophorectomy and estrogen therapy could impact mortality due to breast cancer and cardiovascular disease (CVD) among breast cancer survivors. Elective bilateral oophorectomy at the time of hysterectomy for benign conditions is not uncommon among US women. Methods: We examined the association between pre-diagnosis total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO) and both overall and cause-specific mortality in the Collaborative Breast Cancer Studies cohort. Medical history and prior estrogen use were collected during standardized telephone interviews. Vital status, including date and cause of death, was obtained by linkage with the National Death Index. Multivariate hazard ratios (HR) and 95% confidence intervals (CI) for cause-specific mortality were calculated using Cox proportional hazards regression. Results: Seventeen percent (N = 1,778) of breast cancer survivors (mean age at diagnosis = 63.5) reported pre-diagnosis TAHBSO. During follow-up (mean = 9.5 years), 2,856 deaths occurred, including 1,060 breast cancer deaths and 459 CVD deaths. Breast cancer deaths occurred a median of 5.1 years after diagnosis; CVD deaths occurred further from diagnosis (median = 9.7 years). Women who reported pre-diagnosis TAHBSO had a 16% decrease in all-cause mortality (HR = 0.84; 95% CI: 0.76, 0.92) compared to those with an intact uterus and ovaries. This overall decrease reflected a 27% lower breast cancer mortality among women who never used postmenopausal hormones (HR = 0.73; CI: 0.55, 0.96) and 43% lower CVD risk among women who reported using estrogen (HR = 0.57; CI: 0.39, 0.83) after TAHBSO. Conclusions: Information on prior TAHBSO and estrogen use can inform risk of death from both breast cancer and cardiovascular disease among breast cancer survivors

No difference between red wine or white wine consumption and breast cancer risk.

Epidemiologic studies have reported an increased risk of breast cancer among women who drink alcohol, including wine (1, 2) Two meta-analyses estimated a ∼10% [95% confidence interval (CI), 5-15%] increased risk of breast cancer with each additional 10 grams (∼1 drink) of alcohol/day regardless of beverage type (3, 4). Few studies have evaluated breast cancer risk separately for red and white wine (5-8). There is some evidence of beneficial health effects of red wine from laboratory (9) and epidemiologic studies of heart disease (10) and prostate cancer (11, 12). We evaluated overall alcohol as well as red and white wine consumption to examine beverage-specific effects on breast cancer

A Post-AGB Star in the Small Magellanic Cloud Observed with the Spitzer Infrared Spectrograph

We have observed an evolved star with a rare combination of spectral features, MSX SMC 029, in the Small Magellanic Cloud (SMC) using the low-resolution modules of the Infrared Spectrograph on the Spitzer Space Telescope. A cool dust continuum dominates the spectrum of MSX SMC 029. The spectrum also shows both emission from polycyclic aromatic hydrocarbons (PAHs) and absorption at 13.7 micron from C2H2, a juxtaposition seen in only two other sources, AFGL 2688 and IRAS 13416-6243, both post-asymptotic giant branch (AGB) objects. As in these sources, the PAH spectrum has the unusual trait that the peak emission in the 7-9 micron complex lies beyond 8.0 micron. In addition, the 8.6 micron feature has an intensity as strong as the C-C modes which normally peak between 7.7 and 7.9 micron. The relative flux of the feature at 11.3 micron to that at 8 micron suggests that the PAHs in MSX SMC 029 either have a low ionization fraction or are largely unprocessed. The 13-16 micron wavelength region shows strong absorption features similar to those observed in the post-AGB objects AFGL 618 and SMP LMC 11. This broad absorption may arise from the same molecules which have been identified in those sources: C2H2, C4H2, HC3N, and C6H6. The similarities between MSX SMC 029, AFGL 2688, and AFGL 618 lead us to conclude that MSX SMC 029 has evolved off the AGB in only the past few hundred years, making it the third post-AGB object identified in the SMC.Comment: 4 figures, Fig. 4 color; to appear in the 20 November 2006 Astrophysical Journal Letter

Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis.

BACKGROUND: Several recent studies have provided evidence that polymorphisms in the telomerase reverse transcriptase (TERT) gene sequence are associated with cancer development, but a comprehensive synopsis is not available. We conducted a systematic review and meta-analysis of the available molecular epidemiology data regarding the association between TERT locus polymorphisms and predisposition to cancer. METHODS: A systematic review of the English literature was conducted by searching PubMed, Embase, Cancerlit, Google Scholar, and ISI Web of Knowledge databases for studies on associations between TERT locus polymorphisms and cancer risk. Random-effects meta-analysis was performed to pool per-allele odds ratios for TERT locus polymorphisms and risk of cancer, and between-study heterogeneity and potential bias sources (eg, publication and chasing bias) were assessed. Because the TERT locus includes the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is in linkage disequilibrium with TERT, CLPTM1L polymorphisms were also analyzed. Cumulative evidence for polymorphisms with statistically significant associations was graded as "strong," "moderate," and "weak" according to the Venice criteria. The joint population attributable risk was calculated for polymorphisms with strong evidence of association. RESULTS: Eighty-five studies enrolling 490 901 subjects and reporting on 494 allelic contrasts were retrieved. Data were available on 67 TERT locus polymorphisms and 24 tumor types, for a total of 221 unique combinations of polymorphisms and cancer types. Upon meta-analysis, a statistically significant association with the risk of any cancer type was found for 22 polymorphisms. Strong, moderate, and weak cumulative evidence for association with at least one tumor type was demonstrated for 11, 9, and 14 polymorphisms, respectively. For lung cancer, which was the most studied tumor type, the estimated joint population attributable risk for three polymorphisms (TERT rs2736100, intergenic rs4635969, and CLPTM1L rs402710) was 41%. Strong evidence for lack of association was identified for five polymorphisms in three tumor types. CONCLUSIONS: To our knowledge, this is the largest collection of data for associations between TERT locus polymorphisms and cancer risk. Our findings support the hypothesis that genetic variability in this genomic region can modulate cancer susceptibility in humans.This work was in part supported by a grant from the Italian Association for Research on Cancer (AIRC Veneto Regional fund 2008-2011 to SM and DN).This is the author accepted manuscript. The final version is available from Oxford University Press via http://dx.doi.org/10.1093/jnci/djs22

Prediagnostic use of hormone therapy and mortality after breast cancer.

BACKGROUND: A few studies have observed reduced breast cancer mortality in women who used hormone therapy before diagnosis. Due to the high prevalence of past and current hormone use, it is important to investigate whether these preparations are related to breast cancer mortality. METHODS: To evaluate the influence of prediagnostic use of hormone therapy on breast cancer mortality, a prospective cohort of 12,269 women ages 50 years or more diagnosed with incident invasive breast cancer and residents of Wisconsin, Massachusetts, or New Hampshire were enrolled in three phases beginning in 1988. They were followed for death until December 31, 2005, using the National Death Index. Cumulative mortality and multivariable adjusted hazard rate ratios for breast cancer and other mortality causes were calculated for women according to any hormone therapy use, and for exclusive use of estrogen or estrogen-progestin (EP). RESULTS: During an average 10.3 years of follow-up, 1,690 deaths from breast cancer were documented. Cumulative mortality from breast cancer was lower among hormone therapy users, specifically current users at the time of diagnosis, and EP users, compared with nonusers. Adjusted survival varied by type and duration of hormone therapy before diagnosis. A reduced risk of death from breast cancer was associated with EP preparations (hazard rate ratio, 0.73; 0.59-0.91) and with > or =5 years of EP use (0.60; 0.43-0.84). No association was observed for women who were former or current users of E-alone preparations. CONCLUSIONS: Although use of combined EP preparations increases breast cancer risk, in this study, use of these hormones before diagnosis was associated with reduced risk of death after a breast cancer diagnosis. The better survival among users, particularly of EP, persisted after adjustment of screening, stage, and measured confounders

Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases

Cigarette smoking increases overall mortality, but it is not established whether smoking is associated with breast cancer prognosis

R CrB Candidates in the Small Magellanic Cloud: Observations of Cold, Featureless Dust with the Spitzer Infrared Spectrograph

We observed 36 evolved stars in the Small Magellanic Cloud (SMC) using the low-resolution mode of the Infrared Spectrograph (IRS) on the Spitzer Space Telescope. Two of these stars, MSX SMC 014 and 155, have nearly featureless spectral energy distributions over the IRS wavelength range (5.2-35 um) and F_nu peaking at ~8-9 um. The data can be fit by sets of amorphous carbon shells or by single 600-700 K blackbodies. The most similar spectra found in extant spectral databases are of R CrB, although the spectral structure seen in R CrB and similar stars is much weaker or absent in the SMC sources. Both SMC stars show variability in the near-infrared. Ground-based visual spectra confirm that MSX SMC 155 is carbon-rich, as expected for R CrB (RCB) stars, and coincides with an object previously identified as an RCB candidate. The temperature of the underlying star is lower for MSX SMC 155 than for typical RCB stars. The strength of the C_2 Swan bands and the low temperature suggest that it may be a rare DY Per-type star, only the fifth such identified. MSX SMC 014 represents a new RCB candidate in the SMC, bringing the number of RCB candidates in the SMC to six. It is the first RCB candidate discovered with Spitzer and the first identified by its infrared spectral characteristics rather than its visual variability.Comment: Accepted by ApJ Letters 25 August, 2005, 4 pages (emulateapj), 5 figure

Post-diagnosis dietary factors and survival after invasive breast cancer.

Little is known about the effects of diet after breast cancer diagnosis on survival. We prospectively examined the relation between post-diagnosis dietary factors and breast cancer and all-cause survival in women with a history of invasive breast cancer diagnosed between 1987 and 1999 (at ages 20-79 years). Diet after breast cancer diagnosis was measured using a 126-item food frequency questionnaire. Among 4,441 women without a history of breast cancer recurrence prior to completing the questionnaire, 137 subsequently died from breast cancer within 7 years of enrollment. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated for intake of macronutrients as well as selected micronutrients and food groups from Cox proportional hazards regression models. After adjustment for factors at diagnosis (age, state of residence, menopausal status, smoking, breast cancer stage, alcohol, history of hormone replacement therapy), interval between diagnosis and diet assessment, and at follow-up (energy intake, breast cancer treatment, body mass index, and physical activity), women in the highest compared to lowest quintile of intake of saturated fat and trans fat had a significantly higher risk of dying from any cause (HR = 1.41, 95% CI = 1.06-1.87, P trend = 0.03) for saturated fat; (HR = 1.78, 95% CI = 1.35-2.32, P trend = 0.01) for trans fat intake. Associations were similar, though did not achieve statistical significance, for breast cancer survival. This study suggests that lower intake of saturated and trans fat in the post-diagnosis diet is associated with improved survival after breast cancer diagnosis